Role of botulinum toxin A in improving facial erythema and skin quality

Hanna, Edith; Lin, Xin; Taylor, Jennifer H.; Bertucci, Vince

doi:10.1007/s00403-021-02277-0

Cited by 8 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The precise pathogenesis of erythema in inflammatory facial dermatosis is unknown, but one proposed etiology is that repeated episodes of microcapillary dilation result in loss of vascular tone and subsequent permanent microcapillary dilatation. 6 This may lead to vascular instability and the release of inflammatory cytokines and reactive oxygen species (ROS). 25,26 Our findings demonstrated that most clinicians perceived PN use as effective in vascular stabilization and anti-inflammation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Current practices and perceived effectiveness of polynucleotides for treatment of facial erythema by cosmetic physicians

Lee,

Kim,

Park

et al. 2023

Skin Research and Technology

View full text Add to dashboard Cite

BackgroundPolynucleotides (PN) are increasingly used for the treatment of facial erythema in the Republic of Korea. However, there are limited pre‐clinical and clinical data on the efficacy of polynucleotides for facial erythema. In this study, we investigated the current practice and perceived effectiveness of polynucleotide treatment for facial erythema among cosmetic physicians.MethodsBy conducting a survey among clinicians who use PN in clinical practice, we explored the current practices and assessed the perceived effectiveness of polynucleotides in treating facial erythema.ResultsA total of 557 physicians who used polynucleotides for facial erythema participated in the survey. Polynucleotides were used by 84.4%, 66.4%, and 47.4% of physicians for facial erythema caused by inflammatory facial dermatosis, repeated laser/microneedle radiofrequency, and steroid overuse, respectively. Among those users, 88.1%, 90%, and 83.7% respectively in those same categories answered that polynucleotides were “highly effective” or “effective.” Furthermore, they agreed that polynucleotides have the following properties: wound healing/regeneration (95.8%), protection of skin barrier (92.2%), hydration (90.5%), vascular stabilization (81.0%), and anti‐inflammation (79.5%).ConclusionOur findings showed that cosmetic physicians in the Republic of Korea have used PN as a part of combination treatment for facial erythema resulting from inflammatory facial dermatosis and repeated laser/ microneedle radiofrequency, rather than from steroid overuse. Also, most clinicians agreed that PN was effective for treatment of facial erythema. Given the lack of pre‐clinical and clinical trial evidence, the empirical responses of practicing physicians provide useful information to guide clinical practice and further research.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Several treatment options, such as botulinum toxin, 6 injectable hyaluronic acid, 7 laser, 8 radiofrequency, 9 light‐emitting diodes (LED), 2 therapeutic ultrasound, 10 and plasma therapies, 11 are used for facial erythema. However, their efficacy is unclear due to limited pre‐clinical and clinical data.…”

Section: Introductionmentioning

confidence: 99%

Current practices and perceived effectiveness of polynucleotides for treatment of facial erythema by cosmetic physicians

Lee,

Kim,

Park

et al. 2023

Skin Research and Technology

View full text Add to dashboard Cite

show abstract

“…Interestingly, botulinum toxin can decrease skin flushing and is thus used as a treatment in Frey's syndrome [ 7 ], as well as a treatment against facial erythema in rosacea [ 8 ]. FB has also been described after BTI, with the first case reported in 2012 by Khan et al [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Persistent Facial Blanching after Botulinum Toxin Injection

Mitri¹,

Kälber²,

Enk³

et al. 2022

Case Rep Dermatol

View full text Add to dashboard Cite

We report the case of a 38-year-old male patient who presented with blanching of the face after strenuous exercise or physical exertion. The symptoms regressed in a relaxed state. Three years before presentation, he underwent botulinum toxin injections in the affected areas of the face. Facial blanching is a rare side effect of botulinum toxin injection. The postulated pathophysiology involves different transmitters mainly acetylcholine as well as co-transmitters implicated in vasodilation. Usually, facial blanching resolves shortly after waning of the botulinum toxin. However, in our case, the symptoms persisted for a longer time. Till date, therapy options for post-botulinum facial blanching are lacking, mainly due to the temporary aspect of the disease.

show abstract

“…Oral beta-blockers and injectable botulinum toxin type A (BoNT-A) seem to have a role in treating some cases of erythema. [23][24][25][26][27][28] Additional comments…”

Section: Additional Commentsmentioning

confidence: 99%

Long‐term maintenance treatment of rosacea: experts' opinion

Almeida,

Ianhez,

Dal'Forno

et al. 2023

Int J Dermatology

View full text Add to dashboard Cite

BackgroundRosacea is a chronic inflammatory dermatosis characterized by remissions and flares. Although the rosacea active treatment phase is well established, the long‐term maintenance phase is still challenging.ObjectiveTo discuss and make recommendations on how to treat patients during the long‐term maintenance phase for the main rosacea phenotypes.MethodsA panel of six board‐certified Brazilian dermatologists and one American dermatologist gathered to compose a consensus based upon an initial statement on how to treat rosacea during the long‐term maintenance phase based on the methodology Nominal Group Technique. The experts discussed each factor based upon an initial statement on how to treat rosacea patients in the long‐term maintenance phase. A sequence of comprehensive narrative reviews was performed; a questionnaire preparation about the definition of the maintenance phase and its management was presented; an interpersonal discussion and ranking of the ideas were conducted. Recommendations were made if the specialists had 75% agreement.ResultsThe maintenance treatment phase, which starts by achieving IGA 0 or 1 grades at the active phase, should be considered at least during the 9‐month period after remission. The recommendations of all treatments target this period. Daily skincare regimen and sunscreen are crucial. Active treatment phase should be recommended if signs or symptoms reappear or worsen.ConclusionMaintenance phase success depends on patient's adherence to daily skin care, appropriate treatments, continued follow‐up with dermatologist, and self‐assessment to identify new signs and symptoms indicating disease relapse.

show abstract

Role of botulinum toxin A in improving facial erythema and skin quality

Cited by 8 publications

References 24 publications

Current practices and perceived effectiveness of polynucleotides for treatment of facial erythema by cosmetic physicians

Current practices and perceived effectiveness of polynucleotides for treatment of facial erythema by cosmetic physicians

Persistent Facial Blanching after Botulinum Toxin Injection

Long‐term maintenance treatment of rosacea: experts' opinion

Contact Info

Product

Resources

About